DCLS Testing for Arboviral Disease Detection in Humans

Heather P. Masri, PhD
Emerging Infectious Disease Fellow
Division of Consolidated Laboratory Services
Testing Criteria for Encephalitis

• Any adult or pediatric patient admitted to a hospital with a presumed diagnosis of viral encephalitis, or with focal CNS findings and fever should submit coagulated whole blood or serum sample for diagnostic testing at DCLS following the guidelines:
Recommended Criteria for Suspect Cases of WNV Infection

- **Neuroinvasive disease** requires presence of fever and at least one of the following, as documented by a physician and in the absence of a more likely clinical explanation:
  - Acutely altered mental status (e.g., disorientation, obtundation, stupor, or coma), or
  - Other acute signs of central or peripheral neurologic dysfunction (e.g., paresis or paralysis, nerve palsies, sensory deficits, abnormal reflexes, generalized convulsions, or abnormal movements), or
  - Pleocytosis (increased white blood cell concentration in cerebrospinal fluid [CSF]) associated with illness clinically compatible with meningitis (e.g., headaches or stiff neck).
Recommended Criteria for Suspect Cases of WNV Infection

- **Non-neuroinvasive disease (West Nile Fever)** requires, at minimum, the presence of documented fever, measured by the patient or clinician, the absence of neuroinvasive disease (above), and the absence of a more likely clinical explanation for the illness. Involvement of non-neurological organs (e.g., heart, pancreas, liver) should be documented using standard clinical-laboratory criteria.
Human Arboviral Disease Detection

• Direct Detection
  – Viral nucleic acid in tissues using real time RT-PCR
  – Viral isolation from tissues

• Indirect Detection
  - Production of antibodies
IgM Antibody Capture ELISA (MAC-ELISA)

- Capture Antibody-Anti-Human IgM
- CSF and serum
- Viral Antigen
- Conjugated Antibody-Against viral antigen
- Recent infection
- Remains elevated > 400 days
- PRNT
MIA Principle

• Microsphere based immunologic assays (MIA’s) are similar to ELISAs, except instead of being attached to a plate, the assay components are attached to microspheres (or fluorescent beads), and results are read using a modified flow cytometer.

• Bioassays are performed on microspheres; the beads are all the same size but different colors. Different colored beads can carry different biological tests. The software identifies which viral specific antibody is being produced by the patient.
Microsphere-based assay to detect IgM to WN and SLE viruses in human serum

Beadsets are coupled to an anti-Flaviviral antibody → One beadset is reacted with WNV antigen and the other with SLEV antigen → Add reacted beadsets to IgG-depleted serum and a detector antibody.

- The assay gives concurrent WN and SLE virus IgM values
- All samples reacted on viral and control antigens
- Time of reaction 1.5 hours
IgG ELISA

- Capture Antibody - Goat IgG
- Viral Antigen
- Patient Antibody
- Conjugated Antibody - Anti-Human IgG
- Past infection
- PRNT
Why Run the IgG ELISA?

• Secondary flavivirus infections
• Old versus recent infections
  – IgG POS & IgM NEG indicates a previous flavivirus infection or vaccination
• Additional Confirmation of IgM assay
  – Seroconversion in paired specimens
Plaque Reduction Neutralization Test (PRNT)

- Antibody and live virus are combined in a microtiter plate
- Antibody and virus form a complex (if compatible)
- Complex is plated on cell culture
- Antibody-virus complex blocks the ability of the virus to infect the cell culture
- Formation of plaques is greatly retarded or completely inhibited
- This constitutes a positive PRNT
Plaque Reduction Neutralization Tests (PRNT)

- Clean culture technique established
- Archived specimens are being used for validation

Viral Plaques on Cell Monolayer
WN Human Serological Data

• IgM remains the front-line screening assay
  – IgM detectable in serum & csf by CNS illness onset (99%); IgG Positive by day 7 Post-Onset
• IgM Persistence > 1 Year in 50% cases in 1999 study
  – WNV IgM positives detected in endemic areas could be previous years cases; additional laboratory testing is necessary (IgG ELISA)
• Secondary flavivirus infections are problematic
  – High PRNT to several flaviviruses; no clear “winner.”
Real-Time RT PCR

Denaturation and Primer Binding

Extension and Amplification
Theoretical Depiction of WNV Human Viremia & Immune Response

Virus Assays  
Serology Assays  

WN viremia

IgM

IgG

Neutralizing Ab

ELISA P/N

DAYS POST ONSET

 Days Post Onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10

IgM

IgG

Neutralizing Ab

ELISA P/N

Days Post Onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10

CNS illness

WN viremia

IgM

IgG

Neutralizing Ab

ELISA P/N

Days Post Onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10

CNS illness
Serological Profiling During WNV Infection

• Human viremia is low:
  – Virus isolation is rare

• Human viremia is short-lived
  – WNV nucleic acid is not detectable in the majority of cases by Day 1 of onset

• Generally, viremia is absent when IgM is detectable
# Specimen Submission

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Test</th>
<th>Specimen volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paired-acute phase (0-8 days post onset of illness) and Convalescent-phase (14-21 days after acute specimen sera)</td>
<td>IgM MIA MAC-ELISA IgG ELISA</td>
<td>2 ml sera in plastic tube (preferred) or 5 ml whole coagulated blood</td>
</tr>
<tr>
<td>Acute-phase CSF</td>
<td>IgM-MIA MAC-ELISA Viral isolation Real-time RT-PCR</td>
<td>1.0 ml in plastic tube</td>
</tr>
<tr>
<td>Brain, biopsy or postmortem tissue</td>
<td>Viral isolation Real-time RT-PCR</td>
<td>1 gram</td>
</tr>
</tbody>
</table>
Information Needed for Serological Testing and Interpretation

- Date of onset of disease
- Dates of sample collection
- Travel history
- Vaccination history
- Clinical encephalitis
Arboviral Testing Algorithm

Prior to seasonal detection of arbovirus activity in humans

- **MIA IgM WNV/SLE**
  - Neg: No further WNV/SLE testing
  - POS or Ref. Lab Submission or Special Request

- **MAC ELISA for EEE on all and LAC if patient is < 20 yrs old**
  - Neg: No further WNV/SLE testing
  - POS or Ref. Lab Submission or Special Request

- **WNV, SLE, EEE (LAC) IgG ELISA testing**
  - IgM Neg IgG Neg: No evidence of recent/past infection
  - IgM Neg IgG Pos: No evidence of recent infection Past exposure or immunization
  - IgM Pos IgG Pos: Recent infection PRNT
  - IgM Pos IgG Neg: Result suggestive of recent infection. Need Convalescent serum for PRNT
Arboviral Testing Algorithm

After seasonal detection of arboviral activity in humans (usually Aug)

- MIA
- WNV/SLE
- MAC ELISA
  - EEE & LAC <20
- IgG ELISA
  - For All
- IgM and IgG positive
- PRNT
## History of WNV Surveillance in Virginia

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of Specimens Positive for WNV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Birds</td>
</tr>
<tr>
<td>2000</td>
<td>7</td>
</tr>
<tr>
<td>2001</td>
<td>215</td>
</tr>
<tr>
<td>2002</td>
<td>933</td>
</tr>
<tr>
<td>2003</td>
<td>1042</td>
</tr>
<tr>
<td>2004</td>
<td>26</td>
</tr>
</tbody>
</table>
DCLS Human Arboviral Testing in 2003-2004

- Used MAC-ELISA and IgG ELISA to detect Human IgM and IgG
- RT PCR performed on request or to attempt confirmation:
  - acute CSF and serum
  - post-mortem tissue
- IgM analysis
  - 2003
    - 590 specimens from 383 individuals
    - Positives
      - 28 WNV positive
      - 1 SLE positive
      - 1 EEE positive
      - 4 LAC positive
  - 2004
    - 374 specimens from 279 individuals
    - Positive
      - 8 WNV positive (not all were Virginia residents)
      - 1 LAC positive
    - > 150 bird handlers
Activities For the 2005 Season

• Reduced WNV activity in the Commonwealth in 2005?
• Microsphere Immuno Assay will be used for detection of WNV and SLE IgM positives.
  – Reduced TAT (48 hrs)
  – Will be reported separately from MAC-ELISA and IgG ELISA
• Validation of PRNT in progress
DCLS WNV Surveillance Team